细胞焦亡及其在肝细胞癌发病过程中的作用研究进展

doi:10.3969/j.issn.1672-5069.2024.05.038

Abstract

Abstract: Objective The pyroptosis is an inflammatory programmed cell death,which is characterized by the formation of plasma membrane pores mediated by caspase and the release of a large number of inflammatory mediators.In recent years,the morphological characteristics,induction mechanism and action process of pyroptosis have been gradually revealed. The pyroptosis is related to the progress of many diseases,especially in the pathogenesis of malignant tumors. In this article, we reviewed the pyroptosis and its roles in the occurrence,development and treatment of patients with hepatocellular carcinoma.

Key words: Hepatocellular carcinoma, Pyroptosis, Caspase, Targeting therapy

Zhang Weiping, Ge Hongyan. Pyroptosis and its roles in hepatocellular carcinogenesis[J]. Journal of Practical Hepatology, 2024, 27(5): 797-800.

References

[1] 中华医学会肝病学分会.原发性肝癌三级预防共识(2022年版).中华肝脏病杂志,2022,30(8):832-845.
[2] Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma.Nat Rev Dis Primers,2021,7(1):6.
[3] Torimura T, Iwamoto H. Treatment and the prognosis of hepatocellular carcinoma in Asia. Liver Int, 2022,42(9):2042-2054.
[4] Wu D, Wei C, Li Y, et al. Pyroptosis,a new breakthrough in cancer treatment. Front Oncol,2021,11:2820.
[5] Huang Y, Wang JW, Huang J, et al. Pyroptosis, a target for cancer treatment? Apoptosis,2022, 27(1-2):1-13.
[6] Rao Z, Zhu Y, Yang P, et al. Pyroptosis in inflammatory diseases and cancer. Theranostics,2022,2(9):4310-4329.
[7] Xia X, Wang X, Cheng Z, et al. The role of pyroptosis in cancer: pro-cancer or pro-"host"? Cell Death Dis,2019,10(9):650.
[8] Zychlinsky A, Prevost MC, Sansonetti PJ.Shigella flexneri induces apoptosis in infected macrophages. Nature,1992,358(6382):167-169.
[9] Boise LH, Collins CM. Salmonella-induced cell death: apoptosis, necrosis or programmed cell death? Trends Microbiol,2001,9(2):64-67.
[10] Lyu X, Chen J, He J, et al.Gasdermin D-mediated pyroptosis suppresses liver regeneration after 70% partial hepatectomy. Hepatol Commun,2022,6(9):2340-2353.
[11] de Vasconcelos NM, Van Opdenbosch N, Van Gorp H,et al.Single-cell analysis of pyroptosis dynamics reveals conserved GSDMD-mediated subcellular events that precede plasma membrane rupture. Cell Death Differ,2019,26(1):146-161.
[12] Ruan J.Structural insight of gasdermin family driving pyroptotic cell death. Adv Exp Med Biol,2019,1172:189-205.
[13] Li K, Qiu J,Pan J,et al.Pyroptosis and its role in cervical cancer.Cancers (Basel), 2022,14(23):5764.
[14] Lillo S,Saleh M.Inflammasomes in cancer progression and anti-tumor immunity. Front Cell Dev Biol,2022,10:839041.
[15] Rao Z, Zhu Y, Yang P, et al.Pyroptosis in inflammatory diseases and cancer. Theranostics,2022,12(9):4310-4329.
[16] Lu C, Rong D, Zhang B,et al.Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges andopportunities. Mol Cancer,2019,18(1):130.
[17] Frank D, Vince JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ,2019,26(1):99-114.
[18] Thi HTH, Hong S.Inflammasome as a therapeutic target for cancer prevention and treatment.J Cancer Prev,2017,22(2):62-73.
[19] Liston A, Masters SL. Homeostasis-altering molecular processes as mechanisms of inflammasome activation. Nat Rev Immunol,2017,17(3):208-214.
[20] Place DE, Kanneganti TD. Recent advances in inflammasome biology.Curr Opin Immunol,2018,50:32-38.
[21] Hara H,Seregin SS,Yang D,et al.The NLRP6 inflammasome recognizes lipoteichoic acid and regulates gram-positive pathogen infection. Cell,2018,175(6):1651-1664.
[22] Duncan JA,Canna SW.The NLRC4 inflammasome.Immunol Rev,2018,281(1): 115-123.
[23] Yu P,Zhang X,Liu N,et al.Pyroptosis:mechanisms and diseases.Signal Transduct Target Ther,2021,6(1):128.
[24] Fang Y, Tian S, Pan Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother,2020,121:109595.
[25] Tan Y, Chen Q, Li X, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer.J Exp Clin Cancer Res,2021,40(1):153.
[26] Rathinam VAK,Zhao Y,Shao F.Innate immunity to intracellular LPS.Nat Immunol,2019,20(5):527-533.
[27] Yi YS. Caspase-11 non-canonical inflammasome: a critical sensor of intracellularlipopolysaccharide in macrophage-mediated inflammatory responses.Immunology. 2017,152(2):207-217.
[28] Lu F, Lan Z, Xin Z, et al. Emerging insights into molecular mechanisms underlying pyroptosis and functions of inflammasomes in diseases. J Cell Physiol,2020,235(4):3207-3221.
[29] Wang Y, Gao W, Shi X, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin.Nature,2017,547 (7661):99-103.
[30] Orning P,Weng D,Starheim K,et al.Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death.Science,2018,362(6418):1064-1069.
[31] Hou J, Zhao R, Xia W, et al PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol,2020,22(10):1264-1275.
[32] Chu Q, Jiang Y, Zhang W, et al. Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma.Oncotarget.2016,7(51):84658-84665.
[33] Wei X, Xie F, Zhou X, et al. Role of pyroptosis in inflammation and cancer. Cell Mol Immunol,2022,19(9):971-992.
[34] Vogel A, Meyer T, Sapisochin G, et al.Hepatocellular carcinoma.Lancet,2022,400(10360):1345-1362.
[35] Wei Q, Zhu R, Zhu J,et al. E2-Induced activation of the NLRP3 inflammasome triggers pyroptosis and inhibitsautophagy in HCC cells.Oncol Res,2019,27(7):827-834.
[36] Chen YF, Qi HY, Wu FL. Euxanthone exhibits anti-proliferative and anti-invasive activities in hepatocellular carcinoma by inducing pyroptosis: preliminary results. Eur Rev Med Pharmacol Sci,2018,22(23):8186-8196.
[37] Lammert CR, Frost EL, Bellinger CE, et al. AIM2 inflammasome surveillance of DNA damage shapes neurodevelopment. Nature,2020,580(7805):647-652.
[38] Ma X, Guo P, Qiu Y, et al. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway. Oncotarget,2016,7(24):36185-36197.
[39] Shi X, Wang L, Ren L, et al.Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma hepg2215 cells. Phytother Res,2019,33(5):1413-1425.
[40] Zhang Z, Zhang Y, Xia S, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature,2020,579(7799):415-420.
[41] Lu C, Rong D, Zhang B, et al.Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer,2019,18(1):130.
[42] Chen W, Wei T, Chen Y, et al. Downregulation of IRAK1 prevents the malignant behavior of hepatocellular carcinoma cells by blocking activation of the MAPKs/NLRP3/ IL-1β pathway. Onco Targets Ther,2020,13:12787-12796.
[43] Hage C,Hoves S,Strauss L,et al.Sorafenib induces pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma. Hepatology,2019,70(4):1280-1297.
[44] Shen Z, Zhou H, Li A, et al. Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3. Aging (Albany NY),2021,13(18):22120-22133.
[45] Yan Z, Da Q, Li Z, et al. Inhibition of NEK7 suppressed hepatocellular carcinoma progression by mediating cancer cell pyroptosis.Front Oncol,2022,12:812655.
[46] Zhang Y, Yang H, Sun M,et al. Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome -mediatedpyroptosis. Pharmacol Rep,2020,72(5):1370-1382.
[47] Hu J, Dong Y, Ding L,et al.Local delivey of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment. Signal Transduct Target Ther,2019,4:28.
[48] Henderson JM, Xiang MSW, Huang JC,et al.Dipeptidyl peptidase inhibition enhances CD8 T cell recruitment and activates intrahepatic inflammasome in a murine model of hepatocellular carcinoma. Cancers (Basel),2021,13(21):5495.
[49] Qi S,Wang Q,Zhang J,et al.Pyroptosis and its role in the modulation of cancer progression and antitumor immunity. Int J Mol Sci,2022,23(18):10494.
[50] Hu K, Xu Z,Yao L,et al.Integrated analysis of expression, prognostic value and immune infiltration of GSDMs in hepatocellular carcinoma.Aging (Albany NY),2021,13(21):24117-24135.
[51] Alqahtani A, Khan Z, Alloghbi A, et al. Hepatocellular carcinoma:molecularmechanisms and targeted therapies. Medicina (Kaunas),2019,55(9):526.
[52] Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer,2017,16(1):149.

Pyroptosis and its roles in hepatocellular carcinogenesis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Luo Ke, Ding Li, Liu Mei. Cancerous expression of TTF-1, p53 and p63 proteins in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(3): 434-437.
[2]	Yan Zhen, Zhao Bowen, Lin Guoying, et al. Clinical application of imaging three-dimensional visualization technique in guidance of hepatectomy in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(3): 438-441.
[3]	Wei Ye, Wang Shiyu, Ge Gaohua, et al.. Is the magnetic resonance imaging superior to CT scan in the differential diagnosis of hepatic hemangioma and hepatocellular carcinoma? [J]. Journal of Practical Hepatology, 2024, 27(2): 279-282.
[4]	Ye Mengmeng, Deng Zerun, Zhang Tao. Improved benefit of camrelizumab and apatinib combination in the treatment of patients with advanced hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(1): 96-100.
[5]	Zhou Li, Ding Yunqing, Yuan Fengying, et al. Diagnostic performance of contrast-enhanced ultrasound in determining qualitatively intrahepatic space-occupying lesions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(6): 903-906.
[6]	Su Peihua, Song Meifang, Zhao Caiyan. Is the incidence of hepatocellular carcinoma increased in patients with chronic hepatitis B and nonalcoholic fatty liver diseases? [J]. Journal of Practical Hepatology, 2023, 26(3): 445-448.
[7]	Chen Peng, Liu Huan, Xu Liang. Application of immune checkpoint inhibitors in treatment of patients with advanced hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2023, 26(3): 453-456.
[8]	Zou Chunyan, He Yanpeng, Chai Xiukun, et al. Pathogenesis of hepatocellular carcinoma associated with CDC20 expression [J]. Journal of Practical Hepatology, 2023, 26(1): 95-99.
[9]	Shen Yiliang, Shen Dongyuan, Chen Yongying, et al.. Qualitative evaluation of intrahepatic nodules in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 836-839.
[10]	Shi Qingchun, Pan Limin, Bu Fan, et al.. TCGA-based study of cell necrosis-related genes as prognostic indicators in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(6): 869-872.
[11]	Zheng Xiyan, Du Fei, Lin Zhiqun, et al.. Metabolic syndrome-related risk factor for disease progression of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(6): 877-880.
[12]	Gao Zhengxing, Li Guangxin, Song Chunqing. Prognosis of patients with hepatocellular carcinoma after hepatectomy and sorafenib therapy: prediction by cancerous M6A methyltransferase-like protein 3 levels [J]. Journal of Practical Hepatology, 2022, 25(6): 885-888.
[13]	Wu Tong, Zhang Qiaoli, Qi Xuewei. Systematic analysis of functions of RNA-binding proteins in hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(5): 693-697.
[14]	Bu Fan, Chai Jianbo, Bai Bing, et al. Cyber-based study on ferroptosis-related long non-coding RNA signature predicting prognosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(4): 558-562.
[15]	Yang Ruixu, Fan Jiangao. Epidemiology and screening of nonalcoholic fatty liver disease-related hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(2): 153-156.